#None #Mexico #Immunotherapy #Immorta Bio #Senomune

Immorta Bio: First Human Administration of SenoMune™-0257

In a landmark achievement, Immorta Bio, Inc. has announced the first human administration of its investigational immunotherapy SenoMune™-0257, aimed at combating cellular aging. This revolutionary peptide therapy targets senescent cells—often referred to as "zombie cells"—that accumulate as we age and contribute to various age-related diseases. The initial treatment took place on October 29, 2026, at the Integrative Cancer Centers of America (ICCA) in Mexico as part of an independently initiated clinical study focusing on patients with advanced cancer.

Understanding SenoMune™-0257

SenoMune™-0257 is a proprietary nine-amino-acid peptide designed to stimulate the immune system's recognition and elimination of these dysfunctional cells. As scientists continue to unveil the impacts of aging on health, this immunotherapy not only targets cellular senescence but also aims to rejuvenate overall biological function. This could pave the way for advancing treatments across a variety of conditions, including neurodegenerative diseases, cardiovascular issues, metabolic disorders, and even wound healing.

Immorta Bio developed SenoMune™-0257 leveraging AI-assisted peptide identification to create a therapeutic platform that is both scalable and versatile. The decision to begin human trials with patients facing advanced cancer was strategic, intended to showcase the senolytic capabilities of SenoMune™-0257.

Innovative Approach to Aging

Dr. Thomas E. Ichim, President and Chief Scientific Officer at Immorta Bio, heralded this moment as a groundbreaking step in utilizing the body’s immune responses to target aging-related concerns. He noted, "To our knowledge, this is the first immunotherapy specifically developed to eliminate senescent cells. Unlike traditional small-molecule treatments, our approach leverages the immune system's natural functionality to address the root of age-related diseases."

Supporting this innovation is Dr. Gilberto Lopes, Chief of the Division of Medical Oncology at the University of Miami, who stated that this novel treatment could have far-reaching implications beyond oncology, perhaps establishing a new paradigm in the treatment of aging itself. The collective ambition at Immorta Bio aims to fundamentally alter how medical science approaches aging and age-related diseases.

Future Prospects and Clinical Goals

As Immorta Bio pushes the envelope in age-related medical research, they prepare to broaden the application of their findings. Initial focus on advanced cancer serves as a springboard to extend research into various age-related conditions. The ultimate goal is to harness this novel therapy not only to enhance the health span of individuals but also to meaningfully confront the biology of aging itself.

Boris N. Reznik, Chairman and CEO of Immorta Bio, expressed pride in the milestone achieved, emphasizing the collective effort of the team and the invaluable contributions of participating patients in the trials. The prompt to treat diseases through the lens of aging—rather than one condition at a time—signals a significant shift in medical research and patient care.

The Next Frontier in Health

This first administration of SenoMune™-0257 is a substantial leap toward realizing the dream of extended, healthier lifespans. Immorta Bio's dual-platform approach, including both SenoMune™ and their StemCellRevivify™, encapsulates their mission to treat diseases of aging comprehensively. With ongoing investigations and potential for peer-reviewed support, the implications of their research may transform future therapeutic strategies aimed at not just treating the symptoms of aging but addressing its very essence. As we stand on the brink of potentially life-altering therapies, the world watches with anticipation on how these developments will unfold in real-time clinical settings.